The Pulmonary Arterial Hypertension Market is projected to reach USD 12.18 billion by 2032

From GlobeNewswire: 2025-05-22 09:45:00

The Pulmonary Arterial Hypertension Market was valued at USD 7.91 billion in 2024 and is projected to reach USD 12.18 billion by 2032, with a CAGR of 5.60%. The U.S. market is expected to rise to USD 3.95 billion by 2032, driven by FDA approvals and significant pharmaceutical investments.

Prostacyclin and prostacyclin analogues dominate the PAH market, accounting for 48.10% in 2024. Oral medications hold a 52.11% market share, favored for their ease of use and patient compliance, with phosphodiesterase-5 inhibitors and oral endothelin receptor antagonists being recommended for early to moderate stages of the illness.

North America led the global PAH market in 2024 with a 38.21% share, driven by big pharmaceutical players and supportive healthcare infrastructure. Europe and the Asia-Pacific region are also showing significant growth potential, with Europe benefiting from rapid approval schemes and the Asia-Pacific region expected to have the fastest CAGR. 1. The Aerosol Drug Delivery Devices Market is projected to reach $80.43 billion by 2032, with a compound annual growth rate (CAGR) of 13.19%.

2. The Heparin Market is expected to hit $9.61 billion by 2031, showing a CAGR growth of 2.8%.

3. The Respiratory Care Devices Market is set to reach $43.35 billion by 2032, growing at a CAGR of 7.7%.

SNS Insider offers market research and consulting services globally, providing clients with up-to-date market data, consumer insights, and opinions to make informed decisions.



Read more at GlobeNewswire: Pulmonary Arterial Hypertension Market to Hit USD 12.18